Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
14 mars 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Participate at Upcoming Events in June
01 juin 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Participate at Two Industry Events in May
10 mai 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
26 avr. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Present at World Vaccine Congress Washington 2023
30 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Reports 2022 Year End Results and Recent Company Progress
29 mars 2023 16h00 HE
|
Dyadic International, Inc.
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding...
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
10 nov. 2022 16h00 HE
|
Dyadic International, Inc.
Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for...
Dyadic to Present at Upcoming Industry and Investor Events in November
07 nov. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Updates Market on Recent Scientific Achievements
13 sept. 2022 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...